1Zhou Z, Sehn L H, Rademaker AW, et al. An enhanced International Prognostic Index(NCCN-IPI)for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood, 2013(9):524108.
2Philip T, Gulielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodkins lymphoma. NEngl J Med, 1995(333): 1540-1545.
3Niitsu N, Okamato M, Nakamine H, et al. Simultaneous elevationof the serum concentrations of vascular endothrlial growth factor and interleukin-6 as independent predictors of prognosis in aggressive non-Hodkins lymphoma. Eur J Haematol, 2002, 68(2):91-100.
4Terpos E, Kanellias N, Christoulas D, et al. Pomalidomide:a novel drug to treat relapsed and refractory multiple myeloma. Onco Targets Ther, 2013(6):531.
3Azim HA Jr,de Azambuja E,Colozza M,et al.Long-term toxic effects of adjuvant chemotherapy in breast cancer [J].Ann Oncol,2011,22(9):1939-1947.
4Rodriguez J,Conde E,Gutierrez A,et al.The adjusted International Prognostic Index and beta-2-microglobulin predict the outcome after autologous stem cell transplantation in relapsing/refractory peripheral T-cell lymphoma [J].Haemotologica,2007,92(8):1067.
5Jo JC,Kang BW,Jang G,et al.BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients:comparative analysis of efficacy and toxicity [J].Ann Hematol,2008,87(1):43.
6Abali H,Urün Y,Oksüzolu B,et al.Comparison of ICE(ifosfamide-carboplatin-etoposide)versus DHAP(cytosine arabinoside-cisplatin-dexamethasone)as salvage chemotheraphy in patients with relapsed or refractory lymphoma[J].Cancer Invest,2008,26(4):401-406.
7Pro B,Younes A,Albitar M,et al.Thalidomide for patients with recurrent lymphoma[J].Cancer,2004,100(6):1186-1189.
8Kumar V,Chhibber S. Thalidomide:an old drug with new action[J]. j Chemother, 2011,23(6) : 326-334.
9Morgan GJ, Davies FE. Role of thalidomide in the treatment of pa- tients with multiple myeloma[J], Crit Rev Oncol Mematol,2013,88 Suppl 1 :S14-S22.
10Kaufmann H, Raderer M,Wohrer S,et al. Antitumor activity of rit- uximab plus thalidomide in patients with relapsed/refractory man- tle cell lymphoma[J]. Blood, 2004,104(8) : 2269-2271.